Dopamine agonists for the treatment of cocaine dependence

Amato, Laura; Pani, P.; Solimini, Renata; Vecchi, Simona; Zuccaro, Piergiorgio; Davoli, Marina

doi:10.1002/14651858.cd003352.pub3

Cited by 35 publications

(36 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, amphetamine maintenance decreased cocaine vs money choice in human laboratory studies (Greenwald et al, 2010;Rush et al, 2010), and cocaine use by patients in placebo-controlled double-blind clinical trials (Grabowski et al, 2001;Mariani et al, 2012). Finally, recent meta-analyses of clinical studies have highlighted agonist medications in general, and amphetamine maintenance in particular, as superior in efficacy to many other drug classes as candidate medications for treatment of cocaine dependence (Amato et al, 2007;Amato et al, 2011;Castells et al, 2010;Minozzi et al, 2008;Pani et al, 2011a;Pani et al, 2011b).…”

Section: Evidence For Therapeutic Efficacy Of Ago-nist Medications Tomentioning

confidence: 99%

Agonist Medications for the Treatment of Cocaine Use Disorder

Negus

Henningfield

2014

Neuropsychopharmacol

View full text Add to dashboard Cite

Section: Evidence For Therapeutic Efficacy Of Ago-nist Medications Tomentioning

confidence: 99%

Agonist Medications for the Treatment of Cocaine Use Disorder

Negus

Henningfield

2014

Neuropsychopharmacol

View full text Add to dashboard Cite

“…This may be due in part to many tested medications showing high abuse potential and targeting reward (Sofuoglu, 2010;Amato et al, 2011), rather than the attenuation of stress-related craving (Fox and Sinha, in press). Recent societal changes in the demography of cocaine use also means that the traditional gender gap in both licit and street drug consumption has become much smaller (Degenhardt et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

Sex Differences in Guanfacine Effects on Drug Craving and Stress Arousal in Cocaine-Dependent Individuals

Fox

Morgan

Sinha

2014

Neuropsychopharmacol

102

View full text Add to dashboard Cite

Currently, no FDA-approved medication exists for the treatment of cocaine use disorder. Furthermore, as women become increasingly more at risk for the consequences of cocaine addiction, the need to establish better-tailored treatment medications is paramount. We examine the effects of the alpha2 adrenergic agonist, guanfacine HCl, on responses to stress and drug cue in a group of cocainedependent men and women who also abuse alcohol and nicotine. Forty early abstinent treatment-seeking cocaine-dependent males and females were randomly assigned to receive either daily placebo (12 M/7 F) or guanfacine (2 or 3 mg) (15 M/6 F) for 3 weeks. In week 4, they participated in a laboratory experiment and were exposed to three 10-min guided imagery conditions (stress/stress, cue/cue, and stress/cue), one per day, consecutively in a random, counterbalanced order. Craving, negative emotion, anxiety, and cardiovascular function were assessed at baseline, immediately following imagery exposure, and at various recovery time points. Guanfacine significantly attenuated cocaine craving, alcohol craving, anxiety, and negative emotion following exposure to all three imagery conditions in females, but not males. Guanfacine did, however, reduce sympathetic tone as well as stress and cue-induced nicotine craving and systolic blood pressure (SBP) in both males and females. These findings highlight sex-specific effects of guanfacine on drug craving, anxiety, and negative mood with significant effects in women and not men. The findings suggest further evaluation of guanfacine in the treatment of cocaine use disorder with a specific focus on sex differences in treatment response.

show abstract

“…Drugs that nonselectively and indirectly stimulate D2-like receptors such as d-amphetamine and methamphetamine can reduce cocaine use (Grabowski et al, 2004;Mooney et al, 2009), but themselves possess high abuse liability. Negative results have been obtained using direct-acting D2-like receptor agonists (cf, Amato et al, 2011). D2-like receptor antagonists similarly have limited utility in treating stimulant abuse because of a general lack of efficacy and the emergence of motor side effects that decrease compliance (see, eg, Gawin, 1986;Farde et al, 1992;Barnes and Edwards, 1993;Ohuoha et al, 1997;Grabowski et al, 2000).…”

Section: Introductionmentioning

confidence: 99%

Effects of Oral and Intravenous Administration of Buspirone on Food–Cocaine Choice in Socially Housed Male Cynomolgus Monkeys

Czoty

Nader

2014

Neuropsychopharmacol

View full text Add to dashboard Cite

Drugs acting at D 3 dopamine receptors have been suggested as medications for cocaine dependence. These experiments examined the effects of intravenously and orally administered buspirone, a D2-like receptor antagonist with high affinity for D 3 and D 4 receptors, on the relative reinforcing strength of cocaine in group-housed male cynomolgus monkeys. Use of socially housed monkeys permitted the assessment of whether social status, known to influence D2-like receptor availability, modulates the behavioral effects of buspirone. Buspirone was administered acutely to monkeys self-administering cocaine under a food-drug choice procedure in which a cocaine self-administration dose-effect curve was determined daily. When administered by either route, buspirone significantly decreased cocaine choice in dominant-ranked monkeys. In subordinate monkeys, however, i.v. buspirone was ineffective on average, and oral buspirone increased choice of lower cocaine doses. The effects of buspirone only differed according to route of administration in subordinate monkeys. Moreover, it is noteworthy that the effects of buspirone were similar to those of the D 3 receptor-selective antagonist PG01037 and qualitatively different than those of less selective drugs that act at D2-like or serotonin (5-HT) 1A receptors, suggesting a D 3 and possibly D 4 receptor mechanism of action for buspirone. Taken together, the data support the utility of drugs targeting D 3 /D 4 receptors as potential treatments for cocaine addiction, particularly in combination with enriching environmental manipulations.

show abstract

Dopamine agonists for the treatment of cocaine dependence

Cited by 35 publications

References 86 publications

Agonist Medications for the Treatment of Cocaine Use Disorder

Agonist Medications for the Treatment of Cocaine Use Disorder

Sex Differences in Guanfacine Effects on Drug Craving and Stress Arousal in Cocaine-Dependent Individuals

Effects of Oral and Intravenous Administration of Buspirone on Food–Cocaine Choice in Socially Housed Male Cynomolgus Monkeys

Contact Info

Product

Resources

About